Start-Up Previews (12/04)
Executive Summary
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Artificial Blood, features profiles of Haemostatix, Hemobiotech, Hemocellular Therapeutics and Sangart. Plus these Start-Ups across Health Care: Gloucester Pharmaceuticals, HistoRx, Symphony Medical and Yaupon Therapeutics.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.